CoLucid Pharmaceuticals, Inc. Announces Study Data Documenting Oral Efficacy of Lasmiditan (COL-144), a Selective 5-HT1F Receptor Agonist, in the Treatment of Acute Migraine Attacks
Date: June 9, 2010 Source: PR Newswire
Download the PDF »
CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Date: October 28, 2008 Source: PR Newswire
Download the PDF »
Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
Date: September 5, 2008 Source: PRNewswire
Download the PDF »
CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound
Date: July 1, 2008 Source: PRNewswire
Download the PDF »
Roundtable Brings Together CEOs of Indiana Venture-Backed Life Sciences Companies
Date: January 27, 2007 Source: Business Wire
Read the article on Genetic Engineering News »
InvestMidwest Panel Selects 30 Firms to Present at Venture Capital Forum in April
Date: March 3, 2006 Source: Business Wire
Read the article on FindArticles.com »
$16.5 Million Investment in CoLucid Pharmaceuticals Represents Milestone for Indiana Future Fund, BioCrossroads
Date: January 17, 2006 Source: Business Wire
Download the PDF from BioCrossroads »
CoLucid Pharmaceuticals, Inc. Announces $16.5 Million Series A Financing
Date: January 17, 2006 Source: PRNewswire
Read the article on Biospace.com »